Trial intelligence / Profile preview

Rifamycin SV MMX for Traveler's Diarrhea in Children (6-11 Years)

NCT04026984Phase 2Not yet recruiting

Sponsor
RedHill Biopharma
Start
Jun 2024
Primary completion
Jun 2025
Modality
Small Molecules
01

Overview

A Phase 2 trial of rifamycin SV-MMX in traveler's diarrhea (TD), sponsored by RedHill Biopharma. Planned start Jun 2024; status: not yet recruiting.

02

Drugs

rifamycin SV-MMX
03

Conditions

traveler's diarrhea (TD)

Beyond the preview

Go deeper on NCT04026984.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04026984.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call